CTRI/2019/05/019245尚未招募4 期
Protective effects of telmisartan on cardiac dysfunction in patients with breast cancer on anthracycline (doxorubicin) based adjuvant chemotherapy (PETCAAC Trial) - PETCAAC Trial
ICMR0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with breast cancer
- •Having taken doxorubicin treatment
排除标准
- •Baseline LVEF <50% or NYHA class II-IV.
- •History of heart failure, cardiomyopathy or myocardial infarction.
- •Serum creatinine >=2.5 mg/dl or estimated GFR <30 ml/min/1.73m2
- •Known allergy, hypersensitivity or contraindication to any drugs to ACE I or ARBs.
- •Prior chest radiation or chemotherapy.
- •Deranged LFTs like bilirubin >1.5mg/dl and enzymes 2 to 3 times elevated above upper limit of normal.
- •Pregnancy or breastfeeding.
研究者
相似试验
已完成
不适用
The protective effects of Telmisartan on the cardiovascular systemHypertensionJPRN-C000000331Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine100
已完成
不适用
Study of the Fimasartan effects on cardiovascular events and metabolic syndrome in patients with hypertensioDiseases of the circulatory systemKCT0000529Cheil General Hospital & Women's healthcare center20,000
已完成
不适用
The effect of telmisartan on endothelial function in hypertensive patients.HypertensionJPRN-UMIN000005034Seigo Sugiyama20
终止
2 期
Telmisartan in the management of abdominal aortic aneurysmAbdominal Aortic AneurysmACTRN12611000931976James Cook University208
已完成
不适用
Effect of telmisartan on patients with renal dysfunctioChronic Kidney DiseaseJPRN-UMIN000040875agasaki University Hospital73